The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a huge mover today! The stock decreased 3.76% or $2.58 during the last trading session, reaching $66.08. About 6.04 million shares traded or 231.73% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 107.57% since December 4, 2018 and is uptrending. It has outperformed by 107.57% the S&P500.
The move comes after 9 months negative chart setup for the $6.32 billion company. It was reported on Dec, 4 by Barchart.com. We have $64.10 PT which if reached, will make NASDAQ:ARWR worth $189.72M less.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage
Among 6 analysts covering Arrowhead Pharmaceuticals (NASDAQ:ARWR), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Arrowhead Pharmaceuticals has $7000 highest and $3900 lowest target. $54’s average target is -18.28% below currents $66.08 stock price. Arrowhead Pharmaceuticals had 10 analyst reports since June 28, 2019 according to SRatingsIntel. As per Monday, November 25, the company rating was upgraded by Robert W. Baird. The company was downgraded on Thursday, October 24 by Robert W. Baird. As per Tuesday, October 22, the company rating was maintained by Chardan Capital Markets. On Monday, October 21 the stock rating was maintained by FBR Capital with “Buy”. On Monday, August 19 the stock rating was maintained by B. Riley & Co with “Buy”. On Wednesday, November 13 the stock rating was maintained by FBR Capital with “Buy”. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Neutral” rating given on Tuesday, November 19 by Cantor Fitzgerald. On Sunday, October 20 the stock rating was maintained by Piper Jaffray with “Buy”.
More notable recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Nasdaq.com which released: “Health Care Sector Update for 12/03/2019: MACK,AGTC,VRAY,MDT,ARWR – Nasdaq” on December 03, 2019, also Seekingalpha.com with their article: “Arrowhead Pharmaceuticals reports FY results – Seeking Alpha” published on November 25, 2019, Nasdaq.com published: “Health Care Sector Update for 12/04/2019: HQY, LCI, ARWR, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on December 04, 2019. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were released by: Bioworld.com and their article: “Biopharma companies continue their strong momentum in November – BioWorld Online” published on December 03, 2019 as well as Finance.Yahoo.com‘s news article titled: “Stocks – Intel, Netflix, UnitedHealth Tumble in Premarket Trade – Yahoo Finance” with publication date: December 03, 2019.
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $6.32 billion. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It has a 95.77 P/E ratio. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.